HuGE Literature Finder
Records
1
-
30
| [Correlation Analysis of Ki67 Expression and EGFR Mutation on the Risk of Recurrence and Metastasis in Postoperative Patients with Stage I Lung Adenocarcinoma]. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2023 1 25 (12): 852-861. Xu Lili, Guo Renh |
| Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 1 JCO2202186. Herbst Roy S, Wu Yi-Long, John Thomas, Grohe Christian, Majem Margarita, Wang Jie, Kato Terufumi, Goldman Jonathan W, Laktionov Konstantin, Kim Sang-We, Yu Chong-Jen, Vu Huu Vinh, Lu Shun, Lee Kye Young, Mukhametshina Guzel, Akewanlop Charuwan, de Marinis Filippo, Bonanno Laura, Domine Manuel, Shepherd Frances A, Urban Damien, Huang Xiangning, Bolanos Ana, Stachowiak Marta, Tsuboi Masahi |
| Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation. The oncologist 2023 3 . Hou Zhiwei, Wu Huaguo, Luo Ningning, Li Shuo, Zhang Xiang, Dong Shuai, Zhu Dongyuan, Zhang Hui, Tao Rongj |
| Clinical characteristics and prognostic value of EGFR mutation in stage I lung adenocarcinoma with spread through air spaces after surgical resection. Neoplasma 2023 1 69 (6): 1480-1489. Gao Mao-Gang, Wang Shi-Ze, Han Kai-Hong, Xie Shao-Nan, Liu Qing- |
| Clinicogenomic Landscape of Metastatic Thymic Epithelial Tumors. JCO precision oncology 2023 2 7 e2200465. Ardeshir-Larijani Fatemeh, Schneider Bryan P, Althouse Sandra K, Radovich Milan, Masood Ashiq, Perna Fabiana, Salman Huda, Loehrer Patrick |
| Different prognostic role of EGFR mutation according to the IASLC histologic grade in patients with resected early-stage lung adenocarcinoma. Histopathology 2023 2 . Hong Tae Hee, Hwang Soohyun, Choi Yoon-La, Lee Genehee, Park Sehhoon, Ahn Myung-Ju, Lee Yoonseo, Jeon Yeong Jeong, Lee Junghee, Shin Sumin, Park Seong Yong, Cho Jong Ho, Choi Yong Soo, Kim Jhingook, Shim Young Mog, Cho Juhee, Kim Hong Kw |
| Efficacy of adjuvant chemotherapy in stage II/III NSCLC with EGFR mutation. The Thoracic and cardiovascular surgeon 2023 2 . Matsunaga Takeshi, Takamochi Kazuya, Hattori Aritoshi, Fukui Mariko, Suzuki Ken |
| Risk Factors for Recurrence of Stage I Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma. The Annals of thoracic surgery 2023 2 . Kamigaichi Atsushi, Mimae Takahiro, Tsubokawa Norifumi, Miyata Yoshihiro, Adachi Hiroyuki, Shimada Yoshihisa, Ito Hiroyuki, Ikeda Norihiko, Okada Morihi |
| ROS1 as a possible prognostic biomarker of cervical adenocarcinoma: An exploratory analysis with next-generation sequencing. Gynecologic oncology 2023 2 171 59-66. Machida Hiroko, Matsuo Koji, Tanaka Masayuki, Kitatani Kanae, Takase Akinori, Yokoyama Keiko, Kajiwara Hiroshi, Yasaka Miwa, Ikeda Masae, Yoshida Hiroshi, Hirasawa Takeshi, Mikami Mik |
| EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer is Associated with a High Incidence of Brain Metastasis. Cancer research and treatment 2022 Oct . Kim Hongsik, Park Sehhoon, Jung Hyun Ae, Sun Jong-Mu, Lee Se-Hoon, Ahn Jin Seok, Ahn Myung- |
| Prognostic biomarkers correlated with immune infiltration in non-small cell lung cancer. FEBS open bio 2022 Oct . Xu Fei, Cui Wen-Qiang, Liu Cun, Feng Fubin, Liu Ruijuan, Zhang Jingtao, Sun Chang-Ga |
| Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity-matched analysis in a cohort of 147 recurrences. Thoracic cancer 2022 Sep . Xu Fei, Chen Heng-Chi, Xu Haiyan, Li Junling, Hao Xuezhi, Xing Puyuan, Ying Jianming, Wang Y |
| Biological Difference between L858R and Exon 19 Deletion Contributes to Recurrence-Free Survival of Resected Non-Small Cell Lung Cancer. Oncology 2022 Sep . Masago Katsuhiro, Kuroda Hiroaki, Fujita Shiro, Sasaki Eiichi, Takahashi Yusuke, Shinohara Shuichi, Matsushita Hiroka |
| EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada. Lung cancer (Amsterdam, Netherlands) 2022 Sep 173 58-66. Sara Kuruvilla M, Liu Geoffrey, Syed Iqra, Gwadry-Sridhar Femida, Sheffield Brandon S, Sachdeva Robin, Pencz Alec, Zhan Luna, Hueniken Katrina, Patel Devalben, Balaratnam Karmugi, Khan Khaleeq, Grant Benjamin, Noy Shawna, Singh Karan, Liu Linda, Rakibuz-Zaman Muhammad, Moldaver Daniel, Kate Shanahan Mary, Cheema Parneet |
| Advances in the treatment of postoperative recurrence of non-small cell lung cancer and their impact on survival in Asian patients. The Journal of thoracic and cardiovascular surgery 2022 Aug . Hashimoto Kohei, Ariyasu Ryo, Ichinose Junji, Matsuura Yosuke, Nakao Masayuki, Amino Yoshiaki, Uchibori Ken, Kitazono Satoru, Yanagitani Noriko, Okumura Sakae, Nishio Makoto, Mun Mingy |
| The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010. BMC cancer 2022 Aug 22 (1): 875. Ito Hiroyuki, Date Hiroshi, Shintani Yasushi, Miyaoka Etsuo, Nakanishi Ryoichi, Kadokura Mitsutaka, Endo Shunsuke, Chida Masayuki, Yoshino Ichiro, Suzuki Hidemi, |
| Comprehensive analysis of mutational profile and prognostic significance of complex glandular pattern in lung adenocarcinoma. Translational lung cancer research 2022 Jul 11 (7): 1337-1347. Bai Jinsong, Deng Chaoqiang, Zheng Qiang, Li Di, Fu Fangqiu, Li Yuan, Zhang Yang, Chen Haiqu |
| Prognostic factors in completely resected lymph-node-negative pulmonary adenocarcinoma. Translational cancer research 2022 Jul 11 (7): 2238-2248. Pakvisal Nussara, Chantranuwat Poonchavist, Vinayanuwattikun Chanida, Sitthideatphaiboon Piyada, Teerapakpinyo Chinachote, Shuangshoti Shanop, Benjacholamas Vichai, Pornpattanarak Nopporn, Sriuranpong Viro |
| Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer. BMC cancer 2022 Jul 22 (1): 775. Matsumoto Yoshiya, Kawaguchi Tomoya, Watanabe Masaru, Isa Shun-Ichi, Ando Masahiko, Tamiya Akihiro, Kubo Akihito, Kitagawa Chiyoe, Yoshimoto Naoki, Koh Yasuhi |
| Distribution and favorable prognostic implication of genomic EGFR alterations in IDH-wildtype glioblastoma. Cancer medicine 2022 Jun . Higa Nayuta, Akahane Toshiaki, Hamada Taiji, Yonezawa Hajime, Uchida Hiroyuki, Makino Ryutaro, Watanabe Shoji, Takajo Tomoko, Yokoyama Seiya, Kirishima Mari, Matsuo Kei, Fujio Shingo, Hanaya Ryosuke, Tanimoto Akihide, Yoshimoto Ko |
| Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405). International journal of clinical oncology 2022 Jun . Haratake Naoki, Shimokawa Mototsugu, Seto Takashi, Yoshioka Hiroshige, Yamamoto Nobuyuki, Nakagawa Kazuhiko, Mitsudomi Tetsu |
| A prognostic risk model for glioma patients by systematic evaluation of genomic variations. iScience 2022 12 25 (12): 105681. Zhang Baifeng, Wan Weiqing, Li Zibo, Gao Zhixian, Ji Nan, Xie Jian, Wang Junmei, Wang Bin, Lai-Wan Kwong Dora, Guan Xinyuan, Gao Shengjie, Zhao Yuanli, Lu Youyong, Zhang Liwei, Rodland Karin D, Tsang Shirley |
| Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC. Clinical cancer research : an official journal of the American Association for Cancer Research 2022 7 28 (19): 4312-4321. Jung Hyun Ae, Lim Jinyeong, Choi Yoon-La, Lee Se-Hoon, Joung Je-Gun, Jeon Yeong Jeong, Choi Jae Won, Shin Sumin, Cho Jong Ho, Kim Hong Kwan, Choi Yong Soo, Zo Jae Ill, Shim Young Mog, Park Sehhoon, Sun Jong-Mu, Ahn Jin Seok, Ahn Myung-Ju, Han Joungho, Park Woong-Yang, Kim Jhingook, Park Keunch |
| Cluster analysis of deterioration sites after first-line epidermal growth factor receptor-tyrosine kinase inhibitor in epidermal growth factor receptor mutated non-small cell lung cancer. Contemporary oncology (Poznan, Poland) 2022 7 26 (2): 123-127. Okauchi Shinichiro, Miyazaki Kunihiko, Satoh Hiroa |
| Epithelial TGF? engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features. Nature communications 2022 12 13 (1): 7551. Flanagan Dustin J, Amirkhah Raheleh, Vincent David F, Gunduz Nuray, Gentaz Pauline, Cammareri Patrizia, McCooey Aoife J, McCorry Amy M B, Fisher Natalie C, Davis Hayley L, Ridgway Rachel A, Lohuis Jeroen, Leach Joshua D G, Jackstadt Rene, Gilroy Kathryn, Mariella Elisa, Nixon Colin, Clark William, Hedley Ann, Markert Elke K, Strathdee Douglas, Bartholin Laurent, Redmond Keara L, Kerr Emma M, Longley Daniel B, Ginty Fiona, Cho Sanghee, Coleman Helen G, Loughrey Maurice B, Bardelli Alberto, Maughan Timothy S, Campbell Andrew D, Lawler Mark, Leedham Simon J, Barry Simon T, Inman Gareth J, van Rheenen Jacco, Dunne Philip D, Sansom Owen |
| Genomic Profiling Reveals Novel Predictive Biomarkers for Chemo-Radiotherapy Efficacy and Thoracic Toxicity in Non-Small-Cell Lung Cancer. Frontiers in oncology 2022 12 928605. He Kewen, Zhang Shaotong, Pang Jiaohui, Yin Jiani C, Mu Dianbin, Wang Jun, Ge Hong, Ma Jie, Yang Zhe, Zheng Xiaoli, Dong Lihua, Zhang Junli, Chang Pengyu, Li Li, Tang Shanshan, Bao Hua, Wu Xue, Wang Xiaonan, Shao Yang, Yu Jinming, Yuan Shuang |
| Mutant-Allele Tumor Heterogeneity, a Favorable Biomarker to Assess Intra-Tumor Heterogeneity, in Advanced Lung Adenocarcinoma. Frontiers in oncology 2022 7 12 888951. Wu Xiaoxuan, Song Peng, Guo Lei, Ying Jianming, Li Wenb |
| PD-L1 Expression is not a Predictive Factor for Recurrence in Resected Non-small Cell Lung Cancer. Lung 2022 12 201 (1): 95-101. Motono Nozomu, Mizoguchi Takaki, Ishikawa Masahito, Iwai Shun, Iijima Yoshihito, Uramoto Hideta |
| Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status. BMC cancer 2022 9 22 (1): 966. Isaka Tetsuya, Ito Hiroyuki, Yokose Tomoyuki, Saito Haruhiro, Adachi Hiroyuki, Murakami Kotaro, Miura Jun, Kikunishi Noritake, Rino Yasus |
| The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations. Contrast media & molecular imaging 2022 10 2022 2228744. Song Ruiqiang, Cheng Yanbo, Zheng Tian |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 22, 2023
- Content source: